Directors

Herbert Moessler, Ph.D.

Chairman of the Board of Directors

Dr. Herbert Moessler is one of the founding members of Neuropore Therapies, Inc. and currently serves as the Chairman of the Board of Directors.  He is also an advisor for the EVER Pharma Group in Austria.  Dr. Moessler has extensive experience with all aspects of international pharma business and has devoted his professional career to the development, marketing and sales of therapeutic agents and health products for neurological disorders. Prior to his current assignments, he held the positions of CEO of Neuropore Therapies, CEO of EVER Neuro Pharma, Austria and Staff Scientist at the Institute of Molecular Biology of the Austrian Academy of Sciences.

He received his PhD in Molecular Biology and Genetics from the University of Salzburg, Austria, and his MBA from the Danube University in Krems, Austria.

Hans Meier-Scherling, MBA

Board Member

Mr. Hans Meier-Scherling currently serves as managing partner of the advisory firm Quirinus Capital GmbH focused on corporate finance and M&A services for clients in the healthcare industry. He has extensive experience with international capital markets and M&A transactions with clients from industry and private equity. Prior to forming Quirinus Capital, Mr. Meier-Scherling held the positions of Managing Director of Credit Suisse, Managing Director of Rothschild, Executive Director and Vice President at Morgan Stanley, and Vice President at JP Morgan.

He received his BA in Business Administration from University of Applied Sciences Rhineland, and his MBA from Harvard Business School.

Errol B. De Souza, Ph.D.

President & CEO

Dr. De Souza is currently President, Chief Executive Officer and a member of Board of Directors of Neuropore Therapies, a biopharmaceutical company developing disease modifying treatment for Parkinson’s Disease, Alzheimer’s Disease and other neurodegenerative disorders by targeting molecular mechanisms of autophagy and neuro-inflammation to facilitate clearance of misfolded proteins.  He has substantial experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences, Nasdaq: NBIX) and served as President and Chief Executive Officer of several public (Biodel, Nasdaq: BIOD; Synaptic Pharmaceutical Corp., Nasdaq: SNAP) and private (Archemix) biotech companies.   

Dr. De Souza has raised hundreds of million dollars in capital in private (venture) and public sectors.  Also, he has been involved in taking companies public (Neurocrine Biosciences IPO), executed M&A deals including Synaptic Pharmaceuticals sale to H. Lundbeck A/S, and has served in a number of high-ranking R&D roles, including Senior Vice President and U.S. head of R&D for Aventis (now Sanofi; 1998-2002), co-founder and Executive Vice President of Research and Development at Neurocrine Biosciences (1992-1998), and Head of CNS Diseases Research at DuPont Merck (1990 – 1992).  He has extensive Board experience and serves or has served on the Board of Directors of several private companies and public companies.  

Dr. De Souza received his B.A in physiology and his Ph.D. in neuroendocrinology from the University of Toronto and he received his postdoctoral fellowship in neuroscience from The Johns Hopkins University School of Medicine.